InvestorsHub Logo
Followers 22
Posts 1570
Boards Moderated 0
Alias Born 01/17/2019

Re: CalMustang post# 229884

Sunday, 11/24/2019 7:21:15 PM

Sunday, November 24, 2019 7:21:15 PM

Post# of 427753
But to stay on topic:

Company A
$0 current revenue
No approved drug
No pipeline to speak of other than Inclisiran
Potential sales of $1B in 2024.
--$9.7B--

Company B
$400M+ current revenue
Drug approved for small indication
Pipeline includes AMR102 (V+Statin Combo Pill), Monaresen, and Vascepa 2.0 from Mochida
Potential indications include CVD prevention, Alzheimer's, various cancers, ADHD, recovery for muscular rehabilitation (reduction of lactic acid), etc.
Potential peak sales of $10B+ for CVD indication only (ignoring others).

--$Value??--
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News